FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200260247> ?p ?o ?g. }

• W3200260247 abstract "The aim of this study was to investigate the differential regulation of metabolic parameters between pioglitazone and canagliflozin in relation to their glycaemic efficacies.Drug-naive subjects with T2DM received pioglitazone 15-30 mg/day or canagliflozin 50-100 mg/day monotherapy for 3 months. Those who had a ≥1% reduction in HbA1c were defined as responders and others who had a <1% reduction were defined as non-responders.In the pioglitazone group, baseline BMI, FFA, HOMA-R or adipo-IR was significantly higher, and HDL-C was significantly lower in responders vs non-responders. In the canagliflozin group, baseline HbA1c or FBG was significantly higher, and HOMA-B or age was significantly lower in responders vs non-responders. In pioglitazone responders, significant decreases in HbA1c (from 10.75% to 8.31%), FBG (-29.7%), FFA (-37.7%), non-HDL-C (-13.4%), TG (-30.1%), HOMA-R (-35.6%) or adipo-IR (-38.7%), and increases in BMI (2.8%) or HDL-C (14.2%) were observed. In pioglitazone non-responders, none of the parameters were regulated. In canagliflozin responders, significant decreases in HbA1c (from 11.31% to 8.60%), FBG (32.1%), BMI (-2%) or HOMA-R (-33.8%), and increases in HOMA-B (50%) were observed. In canagliflozin non-responders, significant decreases in BMI (-2.4%), insulin (-21.8%) or HOMA-R (-33.6%) were observed.(i) Glycaemic efficacy of pioglitazone is linked to body weight and atherogenic lipids while this is not the case with canagliflozin. (ii) Responders (or non-responders) to pioglitazone have some distinct features from non-responders (or responders) to canagliflozin. Collectively, a combination of pioglitazone and canagliflozin may compensate for each other's metabolic drawbacks or augment their advantages, thereby achieving overall improvements in the metabolic profiles and pathogenic defects of patients with T2DM." @default.
• W3200260247 created "2021-09-27" @default.
• W3200260247 creator A5015060293 @default.
• W3200260247 creator A5015460546 @default.
• W3200260247 creator A5034914213 @default.
• W3200260247 creator A5054804987 @default.
• W3200260247 creator A5091823897 @default.
• W3200260247 date "2021-10-28" @default.
• W3200260247 modified "2023-09-24" @default.
• W3200260247 title "Complementary effects on glycaemic and non‐glycaemic parameters between responders and non‐responders treated with pioglitazone and canagliflozin in drug‐naive subjects with type 2 diabetes" @default.
• W3200260247 cites W2000262648 @default.
• W3200260247 cites W2066620859 @default.
• W3200260247 cites W2067636490 @default.
• W3200260247 cites W2094683737 @default.
• W3200260247 cites W2105196519 @default.
• W3200260247 cites W2156803989 @default.
• W3200260247 cites W2160234571 @default.
• W3200260247 cites W2571158149 @default.
• W3200260247 cites W2890539106 @default.
• W3200260247 cites W2894878286 @default.
• W3200260247 cites W2896131986 @default.
• W3200260247 cites W2898448926 @default.
• W3200260247 cites W2913840884 @default.
• W3200260247 cites W2967895508 @default.
• W3200260247 cites W2980149573 @default.
• W3200260247 cites W2990309084 @default.
• W3200260247 cites W3003546904 @default.
• W3200260247 cites W3125106283 @default.
• W3200260247 doi "https://doi.org/10.1111/ijcp.14914" @default.
• W3200260247 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34551185" @default.
• W3200260247 hasPublicationYear "2021" @default.
• W3200260247 type Work @default.
• W3200260247 sameAs 3200260247 @default.
• W3200260247 citedByCount "4" @default.
• W3200260247 countsByYear W32002602472023 @default.
• W3200260247 crossrefType "journal-article" @default.
• W3200260247 hasAuthorship W3200260247A5015060293 @default.
• W3200260247 hasAuthorship W3200260247A5015460546 @default.
• W3200260247 hasAuthorship W3200260247A5034914213 @default.
• W3200260247 hasAuthorship W3200260247A5054804987 @default.
• W3200260247 hasAuthorship W3200260247A5091823897 @default.
• W3200260247 hasBestOaLocation W32002602471 @default.
• W3200260247 hasConcept C126322002 @default.
• W3200260247 hasConcept C126894567 @default.
• W3200260247 hasConcept C134018914 @default.
• W3200260247 hasConcept C2777180221 @default.
• W3200260247 hasConcept C2777451236 @default.
• W3200260247 hasConcept C2778384471 @default.
• W3200260247 hasConcept C555293320 @default.
• W3200260247 hasConcept C71924100 @default.
• W3200260247 hasConcept C90924648 @default.
• W3200260247 hasConceptScore W3200260247C126322002 @default.
• W3200260247 hasConceptScore W3200260247C126894567 @default.
• W3200260247 hasConceptScore W3200260247C134018914 @default.
• W3200260247 hasConceptScore W3200260247C2777180221 @default.
• W3200260247 hasConceptScore W3200260247C2777451236 @default.
• W3200260247 hasConceptScore W3200260247C2778384471 @default.
• W3200260247 hasConceptScore W3200260247C555293320 @default.
• W3200260247 hasConceptScore W3200260247C71924100 @default.
• W3200260247 hasConceptScore W3200260247C90924648 @default.
• W3200260247 hasIssue "12" @default.
• W3200260247 hasLocation W32002602471 @default.
• W3200260247 hasLocation W32002602472 @default.
• W3200260247 hasOpenAccess W3200260247 @default.
• W3200260247 hasPrimaryLocation W32002602471 @default.
• W3200260247 hasRelatedWork W1986410768 @default.
• W3200260247 hasRelatedWork W1994230976 @default.
• W3200260247 hasRelatedWork W2003150205 @default.
• W3200260247 hasRelatedWork W2033522292 @default.
• W3200260247 hasRelatedWork W2042938358 @default.
• W3200260247 hasRelatedWork W2121496639 @default.
• W3200260247 hasRelatedWork W2163547766 @default.
• W3200260247 hasRelatedWork W2387349903 @default.
• W3200260247 hasRelatedWork W4240196000 @default.
• W3200260247 hasRelatedWork W8919293 @default.
• W3200260247 hasVolume "75" @default.
• W3200260247 isParatext "false" @default.
• W3200260247 isRetracted "false" @default.
• W3200260247 magId "3200260247" @default.
• W3200260247 workType "article" @default.